<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380779</url>
  </required_header>
  <id_info>
    <org_study_id>BLEEDING042020</org_study_id>
    <nct_id>NCT04380779</nct_id>
  </id_info>
  <brief_title>Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses</brief_title>
  <acronym>BLEEDING</acronym>
  <official_title>Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manuel Monreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for the study of VTE diseases. (FUENTE)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives are:

        -  To establish the prevalence of major bleeding in patients treated with higher than
           recommended thromboprophylaxis doses.

        -  To identify variables associated to higher risk of bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">June 13, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 13, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding events and complications</measure>
    <time_frame>30 days</time_frame>
    <description>Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis
        doses and admitted to hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients infected with COVID-19 treated with higher than recommended
             thromboprophylaxis doses.

          -  Admission to hospital.

        Exclusion Criteria:

          -  Patients treated with ECMO (Extracorporeal membrane oxygenation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Monreal</last_name>
    <role>Study Chair</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mayra Hawkins</last_name>
    <phone>0034915357183</phone>
    <email>riete@shmedical.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manuel Monreal</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Monreal</last_name>
      <phone>0034915357183</phone>
      <email>riete@shmedical.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Foundation for the study of VTE diseases. (FUENTE)</investigator_affiliation>
    <investigator_full_name>Manuel Monreal</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

